News

Biocon Biologics expands diabetes portfolio with FDA approval for Kirsty
Kirsty, Biocon's rapid-acting insulin, is the first FDA-approved interchangeable biosimilar to NovoLog in the US and will be ...
The Pharma Letter6d
FDA approves Biocon BLA for Kirsty
The US Food and Drug Administration approved, the first rapid-acting interchangeable biosimilar product, Kirsty (insulin ...
EquityBulls6d
Biocon Biologics Expands Diabetes Portfolio with FDA Approval of Kirsty™
Biocon Biologics Ltd today announced that the U.S. Food and Drug Administration has approved Kirsty™ (Insulin Aspart-xjhz), ...
Capital Market on MSN6d
Biocon arm gets USFDA approval for insulin, Kirsty
Kirsty is biosimiler to Novolog. It is a rapid-acting human insulin analog indicated to improve glycemic control in adults ...
pharmaphorum3d
FDA okays Viatris' insulin drug as first 'interchangeable' biosimilar
Lantus – said to be the most administered basal insulin across the world – continues to make blockbuster sales, bringing in almost $775 million for Sanofi in the first quarter of this year.
The New York Times1d
Why We Love the Uni-ball Jetstream Pen
Never lend out the Uni-ball Jetstream—it will invariably be “borrowed” permanently.